Updated on 28 May 2025:
'Summary of changes in May 2025' section
The list includes centrally and nationally authorised medicines (CAPs) in the following categories:
- medicines that contain a new active substance that was not contained in any authorised medicine in the EU on 1 January 2011;
- biological medicines authorised after 1 January 2011 - this applies to all biological medicines including biosimilars;
- medicines for which the marketing-authorisation holder is required to carry out a post-authorisation safety study (PASS);
- medicines given conditional approval or authorised under exceptional circumstances and medicines authorised with specific obligations on the recording or monitoring of suspected adverse drug reactions.
Summary of changes in May 2025
The following CAPs have been added to the list:
- Deqsiga – New biological
- Lynozyfic– New active substance, new biological and conditional marketing authorisation
- Vyjuvek - New active substance, new biological, PASS1
The following CAPs have been removed from the list:
• Lorviqua - Five years following its authorisation (May 2019) and switch to non-conditional marketing authorisation
• Beqvez (peviuosly known as Durveqtix) – Withdrawal of the medicinal product
• Cinryze – PASS completed
The following NAPs have been removed from the list:
• None
The following NAPs have been added to the list:
• None
Please note, Annex V - List of hydroxyethyl starch(HES)-containing medicinal products was updated as well following request from Portugal.